Afficher la notice abrégée

Effectiveness and safety of dupilumab for the treatment of severe asthma in a real-life French multi-centre adult cohort

dc.rights.licenseopenen_US
dc.contributor.authorDUPIN, C.
dc.contributor.authorBELHADI, D.
dc.contributor.authorGUILLEMINAULT, L.
dc.contributor.authorGAMEZ, A. S.
hal.structure.identifierCentre de recherche Cardio-Thoracique de Bordeaux [Bordeaux] [CRCTB]
dc.contributor.authorBERGER, Patrick
dc.contributor.authorDE BLAY, F.
dc.contributor.authorBONNIAUD, P.
dc.contributor.authorLEROYER, C.
dc.contributor.authorMAHAY, G.
dc.contributor.authorGIRODET, P. O.
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorRAHERISON-SEMJEN, Chantal
dc.contributor.authorFRY, S.
dc.contributor.authorLE BOURDELLÈS, G.
dc.contributor.authorPROUST, A.
dc.contributor.authorROSENCHER, L.
dc.contributor.authorGARCIA, G.
dc.contributor.authorBOURDIN, A.
dc.contributor.authorCHENIVESSE, C.
dc.contributor.authorDIDIER, A.
dc.contributor.authorCOUFFIGNAL, C.
dc.contributor.authorTAILLE, C.
dc.date.accessioned2021-01-22T10:58:28Z
dc.date.available2021-01-22T10:58:28Z
dc.date.issued2020
dc.identifier.issn0954-7894en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/25959
dc.description.abstractEnBackground Dupilumab is a monoclonal anti‐IL‐4Rα antibody developed for the treatment of severe asthma (SA). An early access programme for dupilumab was opened in France in SA patients experiencing unacceptable steroids side‐effects and/or life‐threatening exacerbations. Objective To assess changes in asthma control between baseline and 12 months of treatment. Methods Multi‐centre (n = 13) retrospective real‐life cohort study. This study is registered on ClinicalTrials.gov (NCT04022447). Results Overall, 64 patients with SA (median age 51, interquartile range [44‐61]; 53% females) received dupilumab as add‐on therapy to maximal standard of care; and 76% were on oral daily steroids at baseline. After 12 months, median asthma control test score improved from 14 [7‐16] to 22 [17‐24] (P < .001); median forced expiratory volume in 1 seconds increased from 58% [47‐75] to 68% [58‐88] (P = .001); and daily prednisone dose was reduced from 20 [10‐30] to 5 [0‐7] mg/d (P < .001). Annual exacerbations decreased from 4 [2‐7] to 1 [0‐2] (P < .001). Hypereosinophilia ≥1500/mm3 was observed at least once during follow‐up in 16 patients (25%), persisting after 6 months in 8 (14%) of them. Increase in blood eosinophil count did not modify the clinical response during the study period. Injection‐site reaction was the most common side effect (14%). Three deaths were observed, none related to treatment by investigators. Conclusion & clinical relevance In this first real‐life cohort study of predominantly steroid‐dependent SA, dupilumab significantly improved asthma control and lung function and reduced oral steroids use and exacerbations rate. Despite limitations due to the retrospective study, these results are consistent with controlled trials efficacy data. Further studies are required to assess the clinical significance and long‐term prognosis of sustained dupilumab‐induced hypereosinophilia.
dc.language.isoENen_US
dc.subjectEPICENE
dc.title.enEffectiveness and safety of dupilumab for the treatment of severe asthma in a real-life French multi-centre adult cohort
dc.title.alternativeClin Exp Allergyen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1111/cea.13614en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed32469092en_US
bordeaux.journalClinical and Experimental Allergyen_US
bordeaux.page789-798en_US
bordeaux.volume50en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.issue7en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.teamEPICENE_BPH
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.exportfalse
bordeaux.COinSctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft.jtitle=Clinical%20and%20Experimental%20Allergy&amp;rft.date=2020&amp;rft.volume=50&amp;rft.issue=7&amp;rft.spage=789-798&amp;rft.epage=789-798&amp;rft.eissn=0954-7894&amp;rft.issn=0954-7894&amp;rft.au=DUPIN,%20C.&amp;BELHADI,%20D.&amp;GUILLEMINAULT,%20L.&amp;GAMEZ,%20A.%20S.&amp;BERGER,%20Patrick&amp;rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée